Dianthus Net Income From Continuing Ops from 2010 to 2026
| DNTH Stock | 53.39 0.03 0.06% |
Net Loss | First Reported 2010-12-31 | Previous Quarter -76.5 M | Current Value -72.6 M | Quarterly Volatility 25.6 M |
Check Dianthus Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Dianthus Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 450.1 K, Interest Expense of 2.7 M or Selling General Administrative of 16.3 M, as well as many indicators such as Price To Sales Ratio of 83.61, Dividend Yield of 0.0 or PTB Ratio of 2.25. Dianthus financial statements analysis is a perfect complement when working with Dianthus Therapeutics Valuation or Volatility modules.
Dianthus | Net Income From Continuing Ops | Build AI portfolio with Dianthus Stock |
The Net Income From Continuing Ops trend for Dianthus Therapeutics offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Dianthus Therapeutics is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest Dianthus Therapeutics' Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of Dianthus Therapeutics over the last few years. It is Dianthus Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Dianthus Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
Dianthus Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | (27,234,211) | |
| Coefficient Of Variation | (93.92) | |
| Mean Deviation | 19,941,475 | |
| Median | (13,109,000) | |
| Standard Deviation | 25,578,202 | |
| Sample Variance | 654.2T | |
| Range | 71.9M | |
| R-Value | (0.76) | |
| Mean Square Error | 298.9T | |
| R-Squared | 0.57 | |
| Significance | 0.0004 | |
| Slope | (3,829,609) | |
| Total Sum of Squares | 10467.9T |
Dianthus Net Income From Continuing Ops History
About Dianthus Therapeutics Financial Statements
Investors use fundamental indicators, such as Dianthus Therapeutics' Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Although Dianthus Therapeutics' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
| Last Reported | Projected for Next Year | ||
| Net Loss | -76.5 M | -72.6 M |
Currently Active Assets on Macroaxis
When determining whether Dianthus Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Dianthus Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dianthus Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dianthus Therapeutics Stock:Check out the analysis of Dianthus Therapeutics Correlation against competitors. For more detail on how to invest in Dianthus Stock please use our How to Invest in Dianthus Therapeutics guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is there potential for Biotechnology market expansion? Will Dianthus introduce new products? Factors like these will boost the valuation of Dianthus Therapeutics. Projected growth potential of Dianthus fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Dianthus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.50) | Revenue Per Share | Quarterly Revenue Growth (0.82) | Return On Assets | Return On Equity |
The market value of Dianthus Therapeutics is measured differently than its book value, which is the value of Dianthus that is recorded on the company's balance sheet. Investors also form their own opinion of Dianthus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dianthus Therapeutics' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Dianthus Therapeutics' market value can be influenced by many factors that don't directly affect Dianthus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Dianthus Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Dianthus Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Dianthus Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.